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EVIDENCE-BASED ANSWER
A
 Which women should we 
screen for gestational diabetes
mellitus? 
  it’s unclear which women we
    should screen. No randomized con-
trolled trials (RCTs) demonstrate that either 
universal screening or risk factor screening 
for gestational diabetes mellitus (GDM) pre-
vents maternal and fetal adverse outcomes. 
Th at said, the common practice of 
universal screening is more sensitive than 
screening based on risk factors (strength 
of recommendation [SOR]: B, 1 random-
ized trial and 3 retrospective cohort studies 
without patient-oriented outcomes). His-
toric risk factors are poor predictors of GDM 
in a current pregnancy (SOR: C, 1 retrospec-
tive cohort study without patient-oriented 
outcomes). 
Evidence summary
No RCTs have evaluated the risks, benefi ts, and 
clinical outcomes of screening for GDM. A re-
view of universal screening compared with risk 
factor screening included 2 retrospective studies, 
1 observational cohort study, and 1 nonconcur-
rent cohort study.1-4 
Risk factor screening misses 
women with GDM 
All 4 studies clearly show that risk factor screen-
ing would miss patients with GDM.1-4 Two 
studies found that the detection rate of GDM in-
creases when universal screening is performed.1,4
One observational study in a multi-
ethnic cohort concluded that risk factor screen-
ing missed 30% of patients with GDM and that 
universal screening increased the detection rate 
from 8.3% to 12.6% (P=.001) compared with risk 
factor screening.1 Similarly, a retrospective study 
of 147 pregnant women with GDM found that 
risk factor screening would have missed 23%.2 
Universal screening diagnoses GDM 
earlier than risk factor screening
One prospective randomized study that com-
pared universal screening (using a 50-g 1-hour 
glucose challenge test) in 1853 women with risk 
factor screening in 1299 women demonstrated 
that nearly half of those with GDM had no his-
torical risk factors and would have been missed 
by risk factor screening in a low-prevalence, 
mostly Caucasian sample. Th e prevalence was 
2.7% in the universal screening group vs 1.45% in 
the risk factor screening group (P<.03). Universal 
screening diagnosed GDM earlier than risk fac-
tor screening (mean gestation 30 ± 2.6 weeks vs 
33 ± 3.7 weeks; P<.05).3
Need for insulin is similar, 
with and without GDM risk factors
A retrospective cohort study demonstrated 
that risk factor screening misses 43% of wom-
en with GDM. Th e study also showed that 
women with GDM who had identifi able risk 
factors and women without identifi able risk 
factors were equally likely to require insulin 
to control their GDM. Adverse birth outcomes 
such as macrosomia and shoulder dystocia or 
cesarean section were similar in patients with 
and without risk factors for GDM.4
Macrosomia and primary C-section 
increase along with glucose intolerance
Th e prospective cohort Hyperglycemia and 
Adverse Pregnancy Outcome (HAPO) Study 
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of 23,316 women at 15 centers in 9 countries 
used the 2-hour 75-g oral glucose tolerance 
test at 24 to 32 weeks’ gestation to clarify the 
risks of adverse outcomes associated with 
varying degrees of maternal glucose intol-
erance. Th e study found a linear increase 
in the risk of macrosomia and primary ce-
sarean section as glucose intolerance levels 
increased from normal to the gestational dia-
betes range.5
Recommendations
Th e US Preventive Services Task Force states 
that evidence is insuffi  cient to advise for or 
against routine screening for GDM.6
Th e American College of Obstetricians 
and Gynecologists considers universal glu-
cose challenge screening for GDM to be the 
most sensitive approach, but notes that some 
pregnant women at low risk may be less likely 
to benefi t from testing.7
Th e Cochrane review protocol states that 
universally accepted screening is controversial 
because of a lack of clearly defi ned, universally 
accepted screening criteria and uncertainty 
about the severity of glucose intolerance at 
which treatment is benefi cial.8                 JFP
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